This study supports p130Cas/ErbB2 complex as a potential breast cancer target and shows the druggability of this protein-protein interaction (PPI) that might benefit from a more advanced optimization effort for therapeutic applications. This evidence concerns the gene ERBB2 and breast carcinoma.